Iovance Biotherapeutics, Inc.(IOVA)

Biotechnology · San Carlos, CA

$13.22-0.94 (-6.61%)

Delayed quote: Oct 6, 2026, 2:30 PM EDT

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.

San Carlos, CA

975 employees

www.iovance.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Frederick G. Vogt

View full financials

IOVA Operating Cash Flow Yield Metrics

OPERATING CASH FLOW YIELD

N/A

OPERATING CASH FLOW YIELD AVG TTM

N/A

OPERATING CASH FLOW YIELD AVG 3Y

N/A

OPERATING CASH FLOW YIELD AVG 5Y

N/A

OPERATING CASH FLOW YIELD AVG 10Y

N/A

OPERATING CASH FLOW YIELD AVG 15Y

N/A

OPERATING CASH FLOW YIELD AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

NAME

MARKET CAP

OPERATING CASH FLOW YIELD

TTM

Iovance Biotherapeutics, Inc. (IOVA)

$5.90B

N/A

Kodiak Sciences Inc. (KOD)vs ›

$5.92B

N/A

Kiniksa Pharmaceuticals International, plc (KNSA)vs ›

$5.85B

3.16%

3.25%

2.26%

2.35%

Ligand Pharmaceuticals Incorporated (LGND)vs ›

$5.96B

2.21%

1.51%

3.26%

5.50%

GRAIL Inc. (GRAL)vs ›

$5.99B

N/A

CG Oncology Inc. (CGON)vs ›

$5.65B

N/A

Rhythm Pharmaceuticals, Inc. (RYTM)vs ›

$6.22B

N/A

RadNet, Inc. (RDNT)vs ›

$5.53B

5.73%

5.92%

6.07%

8.26%

MiniMed Group, Inc. Common Stock (MMED)vs ›

$5.49B

N/A

PTC Therapeutics, Inc. (PTCT)vs ›

$5.32B

N/A

13.90%

Operating Cash Flow Yield Formula & Definition

OCF Yield = TTM Operating Cash Flow / Market Cap

Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).

DATE

OPERATING CASH FLOW YIELD

2014-03-27

84.28%

2014-03-26

82.92%

2014-03-25

82.21%

2014-03-24

84.71%

2014-03-21

78.36%

2014-03-20

75.28%

2014-03-19

79.76%

2014-03-18

82.51%

2014-03-17

84.28%

2014-03-14

88.16%

2014-03-13

85.03%

2014-03-12

80.82%

2014-03-11

79.76%

2014-03-10

74.86%

2014-03-07

77.01%

2014-03-06

83.86%

2014-03-05

81.21%

2014-03-04

97.96%

2014-03-03

109.84%

2014-02-28

121.38%

2014-02-27

113.37%

2014-02-26

114.14%

2014-02-25

112.61%

2014-02-24

112.61%

2014-02-21

119.65%

2014-02-20

123.17%

2014-02-19

127.62%

2014-02-18

125.24%

2014-02-14

115.52%

2014-02-13

104.04%

2014-02-12

111.67%

2014-02-11

118.59%

2014-02-10

127.62%

2014-02-07

137.02%

2014-02-06

135.36%

2014-02-05

135.63%

2014-02-04

134.00%

2014-02-03

124.08%

2014-01-31

135.91%

2014-01-30

102.45%

2014-01-29

103.08%

2014-01-28

111.86%

2014-01-27

115.72%

2014-01-24

117.75%

2014-01-23

117.75%

2014-01-22

102.92%

2014-01-21

90.54%

2014-01-17

86.45%

2014-01-16

83.23%

2014-01-15

75.71%

2014-01-14

78.83%

2014-01-13

79.76%

2014-01-10

83.96%

2014-01-09

83.44%

2014-01-08

78.73%

2014-01-07

70.60%

2014-01-06

69.79%

2014-01-03

70.98%

2014-01-02

68.72%

2013-12-31

63.81%

2013-12-30

60.91%

2013-12-27

59.82%

2013-12-26

69.07%

2013-12-24

70.53%

2013-12-23

70.53%

2013-12-20

74.45%

2013-12-19

70.53%

2013-12-18

68.37%

2013-12-17

70.53%

2013-12-16

61.75%

2013-12-13

70.53%

2013-12-12

81.71%

2013-12-11

77.91%

2013-12-10

71.05%

2013-12-09

63.21%

2013-12-06

60.91%

2013-12-05

64.42%

2013-12-04

71.97%

2013-12-03

76.14%

2013-12-02

90.54%

2013-11-29

79.57%

2013-11-27

79.67%

2013-11-26

90.54%

2013-11-25

122.94%

2013-11-22

133.74%

2013-11-21

134.00%

2013-11-20

128.85%

2013-11-19

134.00%

2013-11-18

100.00%

2013-11-15

125.24%

2013-11-14

151.39%

2013-11-13

175.61%

2013-11-12

183.44%

2013-11-11

185.50%

2013-11-08

185.50%

2013-11-07

188.69%

2013-11-06

188.15%

2013-11-05

175.61%

2013-11-04

164.63%

2013-11-01

151.39%

2013-10-31

138.64%

2013-10-30

120.17%

2013-10-29

123.09%

2013-10-28

123.09%

2013-10-25

121.73%

2013-10-24

119.73%

2013-10-23

119.73%

2013-10-22

95.23%

2013-10-21

97.82%

2013-10-18

92.77%

2013-10-17

89.83%

2013-10-16

89.83%

2013-10-15

89.83%

2013-10-14

89.83%

2013-10-11

77.00%

2013-10-10

69.55%

2013-10-09

59.23%

2013-10-08

56.44%

2013-10-07

53.90%

2013-10-04

49.00%

2013-10-03

56.74%

2013-10-02

59.89%

2013-10-01

82.92%

2013-09-30

82.29%

2013-09-27

106.73%

2013-09-26

134.75%

2013-09-25

134.75%

2013-09-24

107.80%

Operating Cash Flow Yield: N/A

IOVA Operating Cash Flow Yield Chart

IOVA Operating Cash Flow Yield Metrics

IOVA Competitors' Operating Cash Flow Yield

Operating Cash Flow Yield Formula & Definition

IOVA Operating Cash Flow Yield History

Related Metrics